This week, Sarepta Therapeutics Inc (NASDAQ:SRPT) dosed its first patient with commercial Exondys 51 (eteplirsen), the biotech firm’s intravenous infusion Duchenne muscular dystrophy …
In a research report released yesterday, Wedbush analyst Henry Coffey initiated coverage on shares of LendingClub Corp (NYSE:LC) with an Underperform rating and …
The biotech world is full of news today, and analysts are accordingly prompted to share insights on Catabasis Pharmaceuticals Inc (NASDAQ:CATB) and Alcobra Ltd (NASDAQ:ADHD). …
Wedbush analyst Michael Pachter sheds light on Amazon.com, Inc.
XOMA Corp (NASDAQ:XOMA) recently released initial data from its single-dose trials for XOMA 358, the firm’s pipeline drug designed to treat rare endocrine …
Analysts are weighing in on Novavax, Inc. (NASDAQ:NVAX) and XOMA Corp (NASDAQ:XOMA), as shares of both companies fell sharply today due to various …
In a research report published Wednesday, Wedbush analyst Liana Moussatos downgraded shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) from Outperform to Neutral, while reducing the …
We see Idera’s next generation antisense platform as a driver of future value for the company, says Wedbush
Omeros Corporation (NASDAQ:OMER) shares tumbled nearly 12% today, after the company announced a $40-million underwritten public offering of its common stock at a …
Wedbush analyst Michael Pachter was out with a favorable report on shares of video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), reiterating an Outperform rating and raising …
